Join
Live feed
·
INSIDERFilingvia Quantisnow
Zentalis Pharmaceuticals Inc. logo

Chief Scientific Officer Lackner Mark sold $24,591 worth of shares (14,368 units at $1.71) and was granted 335,907 shares, increasing direct ownership by 168% to 512,856 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ZNTL· Zentalis Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZNTL (Zentalis Pharmaceuticals Inc.) and more on Quantisnow.